Home
NewsNewsAlpha Controls & Instrumentation Inc. has been selected by FertiTech Canada Inc. as its third-party calibration partner for Nilotech temperature probes. The partnership channels Canadian IVF laboratories and fertility clinics using Nilotech equipment to Alpha Controls for professional, accredited calibration services, while FertiTech continues to handle equipment supply and gas sensor calibration.
Alpha Controls & Instrumentation Inc. has announced a new partnership with FertiTech Canada Inc., under which Alpha Controls has been selected as the company’s designated third-party calibration provider for Nilotech temperature probes used in IVF laboratories and fertility clinics across Canada.
The agreement formalises a clear division of responsibility between the two organisations. FertiTech Canada will continue to provide customers with Nilotech equipment, technical support, and in-house gas sensor calibration. Customers requiring calibration services for their Nilotech temperature probes will be directed to Alpha Controls a Canadian, family-owned instrumentation and calibration company with more than 45 years of industry experience and ISO/IEC 17025-accredited calibration through A2LA.
For IVF laboratories and fertility clinics in Canada, temperature accuracy is not a peripheral concern, it is a foundational requirement of laboratory quality and patient safety. The precise thermal environments maintained by incubators, warming stages, and cryogenic equipment directly affect the conditions in which gametes and embryos are handled and stored. Calibration of temperature probes against traceable, documented standards is a critical part of maintaining that accuracy.
Under the new arrangement, Alpha Controls becomes the specialist calibration resource for customers using Nilotech temperature probes distributed by FertiTech. The partnership gives those customers access to professional, accredited calibration services without requiring FertiTech to build that capability in-house, a model that reflects Alpha Controls’ growing role as a trusted third-party calibration partner for manufacturers and technology providers serving regulated markets.
Marc Brand, VP of Sales & Service at Alpha Controls & Instrumentation, described what the selection represents:
“We’re incredibly proud to be trusted by FertiTech to support their customers. When another company trusts you to look after their customers, that’s a pretty meaningful endorsement. It speaks to the confidence they have in our technical expertise, our people, and the level of service we provide.”
In the UK, a Ten Minute Rule Bill has been introduced in the Commons to create a legal right to paid time off for fertility treatment, aiming to standardize access to time‑sensitive appointments and reduce reliance on employer discretion. The proposal seeks House permission to proceed and spotlights workplace rights during Fertility Awareness Week.
Columbia University Fertility Center has achieved the first confirmed pregnancy using an AI-guided sperm recovery method in a man with azoospermia, as detailed in The Lancet. The STAR system combined advanced imaging, microfluidics, and robotics to retrieve two viable sperm, enabling embryo creation after prior failed surgical and manual attempts.
British Columbia's free IVF program exhausts 2025 funding within months of launch. At least one approved clinic stops accepting new applications. Applicants face aging-out risks and must wait until spring 2026 for next funding allocation.
Singapore’s MOH approves 13 additional genetic conditions for testing before embryos are implanted during IVF, enhancing reproductive genetic screening options.
National Health Service-funded IVF in England varies across regions in terms of access, cycle definitions, and eligibility. While Integrated Care Boards follow NICE guidelines, local implementation differs to meet specific population needs. Current policy reviews aim to enhance consistency and ensure continued access to fertility services across England.
INVO Fertility looks to acquire Family Beginnings to advance its national expansion and broaden innovative care access.
